EI

267.6

+0.3%↑

SHL.DE

49.9

-0.72%↓

ARGX

544.8

+0.41%↑

FRE

39.5

+0.36%↑

PHIA

23.56

+1.12%↑

EI

267.6

+0.3%↑

SHL.DE

49.9

-0.72%↓

ARGX

544.8

+0.41%↑

FRE

39.5

+0.36%↑

PHIA

23.56

+1.12%↑

EI

267.6

+0.3%↑

SHL.DE

49.9

-0.72%↓

ARGX

544.8

+0.41%↑

FRE

39.5

+0.36%↑

PHIA

23.56

+1.12%↑

EI

267.6

+0.3%↑

SHL.DE

49.9

-0.72%↓

ARGX

544.8

+0.41%↑

FRE

39.5

+0.36%↑

PHIA

23.56

+1.12%↑

EI

267.6

+0.3%↑

SHL.DE

49.9

-0.72%↓

ARGX

544.8

+0.41%↑

FRE

39.5

+0.36%↑

PHIA

23.56

+1.12%↑

Search

Sanofi SA

Open

BrancheGesundheitswesen

102.7 0.18

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

101.2

Max

103.64

Schlüsselkennzahlen

By Trading Economics

Einkommen

-2.3B

499M

Verkäufe

-6.5B

7.6B

KGV

Branchendurchschnitt

23.663

73.239

EPS

1.31

Dividendenrendite

3.7

Gewinnspanne

6.539

Angestellte

82,878

EBITDA

-3.7B

563M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+11.4% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

3.70%

3.06%

Nächstes Ergebnis

24. Apr. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-2.2B

129B

Vorheriger Eröffnungskurs

102.52

Vorheriger Schlusskurs

102.7

Nachrichtenstimmung

By Acuity

32%

68%

87 / 386 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

Sanofi SA Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

20. März 2025, 06:43 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi to Acquire Autoimmune Disease Treatment From Dren Bio for Up to $1.9 Billion

5. Feb. 2025, 13:41 UTC

Ergebnisse

Santander Shares Get Boost From Buyback, Better-Than-Expected Results -- 2nd Update

5. Feb. 2025, 07:10 UTC

Ergebnisse

Santander Plans $10.4 Billion in Buybacks After Results Beat Expectations -- Update

5. Feb. 2025, 06:39 UTC

Ergebnisse

Santander Plans $10.4 Billion in Buybacks After Results Beat Expectations

26. März 2025, 06:19 UTC

Market Talk
Ergebnisse

Santander Surpasses 100 Billion-Euro Valuation Milestone -- Market Talk

25. März 2025, 10:08 UTC

Market Talk

Santander Needs Step-Up in Profitability to Fully Close Discount -- Market Talk

20. März 2025, 09:00 UTC

Top News

'Anti-Woke' in the U.S., DEI at Home: the New Playbook for European Companies -- WSJ

20. März 2025, 06:05 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi: Deal Seeks to Broaden Immunology Pipeline

20. März 2025, 06:05 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi to Make Potential Future Payments Totaling $1.3B Upon Reaching Milestones

20. März 2025, 06:04 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi to Pay $600M Upfront

20. März 2025, 06:02 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi to Buy Dren Bio's Bispecific Myeloid Cell Engager

20. März 2025, 06:00 UTC

Akquisitionen, Fusionen, Übernahmen

Press Release: Sanofi To Acquire Dren Bio's Bispecific Myeloid Cell Engager For Deep B-cell Depletion, Broadening Immunology Pipeline >SAN.FR

18. März 2025, 09:33 UTC

Heiße Aktien

Stocks to Watch Tuesday: Nvidia, BYD, Santander, Google -- WSJ

17. März 2025, 23:00 UTC

Top News

Santander Pushes to Expand U.S. Operations by Utilizing Verizon Customer Base -- WSJ

13. März 2025, 09:50 UTC

Ergebnisse

Santander Approves Final Cash Dividend Per Share of EUR11 cents

13. März 2025, 09:49 UTC

Ergebnisse

Santander Increased 2024 Cash Payments by 19%

24. Feb. 2025, 08:56 UTC

Market Talk
Ergebnisse

European Banks' Quarterly Beats Confirm Momentum -- Market Talk

24. Feb. 2025, 08:30 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Southern European Banks' Strong Finish to 2024 Confirms Attractiveness -- Market Talk

19. Feb. 2025, 06:35 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi: Transaction Remains Subject to Obtaining Customary Regulatory Approvals

19. Feb. 2025, 06:34 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi: Closing Is Expected to Take Place in 2Q at the Earliest

19. Feb. 2025, 06:34 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi: Terms of Transaction Remain Unchanged From Those Previously Disclosed

19. Feb. 2025, 06:33 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi to Remain Significant Shareholder in Opella Consumer Business

19. Feb. 2025, 06:33 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi: Bpifrance to Participate as Minority Shareholder With 2% Stake in Opella

19. Feb. 2025, 06:33 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi: This Follows Completion of Required Social and Corporate Procedures

19. Feb. 2025, 06:32 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi Signs Deal for Sale of 50% Controlling Stake in Opella to CD&R

19. Feb. 2025, 06:31 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi, CD&R Sign Opella Share Purchase Agreement

14. Feb. 2025, 10:55 UTC

Market Talk
Ergebnisse
Akquisitionen, Fusionen, Übernahmen

NatWest CEO Confident on Organic Growth Prospects -- Market Talk

5. Feb. 2025, 07:48 UTC

Market Talk
Ergebnisse

Santander's Results, Guidance, Return Plans All Look Strong -- Market Talk

5. Feb. 2025, 06:01 UTC

Ergebnisse

Santander: Franco Joins Getnet From Canadian Fintech Company Nuvei

5. Feb. 2025, 06:01 UTC

Ergebnisse

Santander: Getnet's Current CEO, Kush Saxena, Has Decided to Resign

Peer-Vergleich

Kursveränderung

Sanofi SA Prognose

Kursziel

By TipRanks

11.4% Vorteil

12-Monats-Prognose

Durchschnitt 115.186 EUR  11.4%

Hoch 125 EUR

Tief 92 EUR

Basierend auf 13 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Sanofi SA – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

13 ratings

9

Buy

4

Halten

0

Sell

Technischer Score

By Trading Central

101.1 / 105.96Unterstützung & Widerstand

Kurzfristig

Bearish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

87 / 386 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.